During the 8th annual Microbiome Movement Drug Development Europe, held in Barcelona (Spain), Microbiomepost conducted an exclusive interview with Daniel Brownell, Senior Director of Research & Development at AOBiome Therapeutics, a life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. The core of AOBiome Therapeutics technology is ammonia oxidizing bacteria, formulated as a topical suspension of bacteria applied topically to the skin to treat atopic dermatitis.
Challenges in clinical trial execution for Live Biotherapeutics
An exclusive interview with Daniel Brownell, Senior Director of Research & Development at AOBiome Therapeutics, whose core technology is ammonia oxidizing bacteria, formulated as a topical suspension of bacteria applied topically to the skin to treat atopic dermatitis.
Most recent
Gastroenterology
26 April 2024
HCPs Area
Industry
- Read more about atopic dermatitis, inflammation, LBP
Gastroenterology
26 April 2024
